

Fanvestments Corporation
Global Investments - Global Returns
Invest today, Build Wealth Forever

FVAM Fund Quarterly Portfolio Report
Q2 - 2024

Fanvestments Private Diversified Alternative Investment Fund (FVAM)

This Report describes the Fanvestments Private Alternative Investment Fund (the "Fund", "FVAM"). Fanvestments Corporation (the "Management"), a Rhode Island S-Corporation, serves as the Fund's Management Business. The following summary highlights information about the fund, during the 2nd & 3rd Quarter of 2024, and info about the fund's investment strategy and expectations. Except where the context otherwise requires or indicates, in this report, (i) "Fanvestments," "the Business," "we," "us", "Firm", "management" and "our" refer to Fanvestments Corporation and/or owner, and its Primary offering, with respect to FVAM, a Private Alternative Investment Fund, referred to as "the Fund", "the portfolio", or "FVAM".

Contact and Social Media:

Fanvestments, Corporation

Matthew Fanning – Owner / Founder / CIO / Fund Manager

mfanning@fanvestments.com

www.fanvestments.com

Twitter: @fanvestments

facebook.com/fanvestments

Instagram: @fanvestments

PRINCIPAL INVESTMENT STRATEGY

The FVAM Fund consists of a diversified portfolio primarily focused on investing long within individual stocks & ETFs, "Equity long-bias", with small exposure towards hedging, as well as occasional exposure between commodities, fixed income and currencies. FVAM has a dual goal of capital appreciation AND preservation, looking for strong returns while applying a layer of defense to handle all types of economic and global financial cycles and market volatility. The fund applies multiple strategies, from fundamental research looking at earnings, revenue, growth rates, and valuation, to analyzing historical data and projecting future expectations. Combining fundamentals with technical analysis ("technical"), studying charts and price action for trends & patterns, as well as trend change, price and timeframe analysis, overbought and oversold indicators, and volume spikes leading to capitulation. The macro environment is very important as well, and will overlay macro research on top of other research and overall portfolio analysis. Other strategies, more of a focus within a sector, such as biotech, looking for companies that are trying to find cures/preventions for major diseases. Within Technology, to find innovation helping to disrupt and shape the future, such as AI, Big Data, Cloud, Security, Analytics, FinTech (financial technology). Price and Returns tend to trump timeframes, "PriceFrame", being a far more important metric than timeframe, but the fund does expect to hold most core investments for multiple years, mid-to-long term.

The Fund is actively-managed with a blended investment style, looking for Growth at a great Value, Growth-on-Sale, utilizing more of a "buy the blood" strategy, buy low-sell high, as a fundamental mindset. The fund will also seek to find opportunities within event-driven strategies, such as potential buy-outs/mergers, FDA approvals, momentum and fund flows, as well as unusual options action. Part of the investment style is to bring together a diversified multi-asset "401k retirement" portfolio approach, combined with hedge fund, institutional style investment involving individual stock picking alongside minimal hedging against general market risk, as well as having low market correlation producing independent fund-specific returns. Only on a limited basis, and kept to very small exposure at most times, the fund does use multiple hedging strategies to protect from general stock market volatility, as well as downside risk within individual positions, or macro issues such as economic cycles, recessions, geopolitics. Currently any short exposure in the fund utilizes options vs outright selling short, such as index/ETF options, VIX (volatility) options, positional & sector hedges. Overall hedging exposure is kept low, utilizing more of a hedge by allocation strategy, such as Diversification and Position sizing, asset allocation management, always monitoring positional exposure relative to the risk of that position and overall portfolio size. As well as other portfolio management strategies such as performance monitoring and risk management, constantly studying fund volatility and day-to-day performance statistics.

The FVAM fund, is designed to be an all-weather style fund, "all-markets", meaning the fund can navigate through all types of economic and market cycles, taking advantage of the upside and withstanding periods of major market selloffs. FVAM is not a "thematic" fund, and its diversified, risk-sensitive strategies are built to suit investors of all-ages, from younger and just starting to invest, through all stages of retirement and life. From the start, the fund always had intention to relate to the "conservative" retiree investor, where this group, at least to me, seems to give up an extreme amount of capital growth in the years where it's needed most. FVAM is built to be worthy of a large portion of an overall portfolio, to pair perfectly alongside something like a 60-40 style strategy, and is built to be a forever investment. Since FVAM is not intending to mirror, or match the assets or performance of any other index or ETF, the fund's performance will not have any intention to directly match the performance of any other investment vehicle, ETF, or Index or have the same timing as the overall markets. FVAM's intent is to have created its own unique investment vehicle, with individual assets selected by Fanvestments Management, reduced market correlation, and less volatility vs market indices. Although compared to the S&P 500, this is not the fund's true benchmark, as the index is strictly a US large-cap index. FVAM is diversified among multiple market caps and sectors, multiple strategies, and has international exposure. Utilizing a dynamic and perpetually improving investment strategy combining increased Portfolio Quality, constant Portfolio analysis, non-stop financial market study, risk and allocation management, along with relentless analysis of performance metrics, statistics, with the goal of perpetual improvement. Matching up technical analysis for timing with Fundamental analysis for valuation, and overlaying Macro environment research to help find Global trends and determine overall Market risk.

Make the Money - Make More Money, Don't lose the Money .

Q2 Highlights

For the 2nd Quarter of 2024, the FVAM fund finished positive, with a +1.5% return. FVAM had a down April, then back-to-back positive months in May & June. The fund was down -2.25% in April, up 1.02% in May, and up 2.7% in June. On a relative basis for the year thru the 2nd Quarter, based on an internal performance tracker of ~40 indexes/sectors, FVAM was outperforming less than half of the components, but was on par with S&P-LowVol, and outperforming major bond funds like TLT and HYG, ARKK, as well as XLY & XLRE. For the 2nd Quarter, the S&P 500 was up 4.4%, the Dow Jones was down -1.6%, with the small cap etf IWM, down -3.3%. The ACWX etf, which tracks stocks around the world excluding the United States, was down -0.3%, w/the RSP (equal-weight SP500) down -2.9%. Cathie Wood's ARKK thematic growth & innovation fund, was down 12%. Although there is no attempt to match the performance or timing of the S&P 500, along with mixed-asset exposure, multi-cap and multi-strategy, lower risk & volatility, and with equity exposure around 80-85% of the fund, the fund's performance and volatility is analyzed against the index, an all-stock and strictly large-cap index. Other reference points, more relative and important benchmarks for the fund, are Warren Buffett's Berkshire Hathaway, as well as SPLV, which is the S&P 500 Low Volatility etf. A less volatile alternative to the SP500 is a major goal/focus of the FVAM fund, making the SPLV a top benchmark for the fund. Using the BRK/b shares, Berkshire was down -3.2% for the 2nd quarter, w/SPLV down -1.3. Through July '24, BRKb was up 21%, with the SPLV up +7%. FVAM was up 6.2%, losing ground in January, w/strong months in Feb, June, & July.


The fund's YTD top performing investments at the end of 2nd quarter, best performers first, were Amazon (AMZN), Novo Nordisk (NVO), Disney (DIS) as the top three. Following them up was Grayscale Ethereum (ETHE), Cleanspark (CLSK), Netflix (NFLX), Nextera Energy (NEE), Arm Holdings (ARM), Gamestop (GME) and CVS (CVS, shortside) rounding out the top 10. Of those top 10; DIS, NFLX, NEE, ARM, GME, CVS, CLSK, ETHE, have been sold, all for gains. Disney the best of that group, 6th best performer for the year. Sold the very top of the year here, DIS had dropped to \$85 from April to August, at \$96 recently and back on the watch list. Amazon remains a core-position, running between 9-10% of overall fund, and still have full conviction Amazon will continue to be a secular winner. In the quarter, Target (TGT), Zscaler (ZS) & Tesla (TSLA) were sold/reduced, buying back into Tesla in May. Fund added to XBI (biotech etf), and bought/initiated positions in Gilead (GILD), Icahn Enterprises (IEP), and New York Community Bank (NYCB). Looking further into Gilead, fund's 3rd largest & a longer-term core position and quickly the fund's 2nd best position for the year. Fund started buying GILD in early May '24 thru June around \$66, w/an avg cost ~65. Reduced position small in Aug ~\$73, and in Sept ~\$82. Latest big news was their HIV prevention twice-yearly shot, Lencapavir, surpassed phase 3 trial expectations **with 100%** efficacy. Looking for 6-8% sales growth with '25 EPS growth of 30%, Q2 '24 eps was up 55%, with some one-offs tho. Would get '25 revenue above \$30 Billion, and '25 eps up to \$7-\$8. 1-2 year target @ \$140 using 25x price-to-fcf (free cash flow), industry avg is @ 26x with S&P 500 @ 32x p-fcf. Gilead's peg ratio has averaged just 0.5 in the last 5 years, if using 0.75x '26 estimates, would get GILD above \$240. Believe their portfolio and pipeline is undervalued, and also comes with a 3.8% dividend yield. Technicals look strong/bullish, but price is coming up towards previous highs/resistance ~\$90, reaching highs just above \$123 back in June 2015.

Can read more about Gilead here: [Gilead Investor Relations](#)



Looking into Q3 2024, new positions were initiated in Genius Sports (GENI), Nike (NKE), Vertiv (VRT) and increased crypto exposure via Microstrategy (MSTR), Proshares Ultra Bitcoin (BITU), and Osprey Solana (OSOL). Fund added to Tesla (TSLA) and Icahn Enterprises (IEP), and got back into Nvidia (NVDA) and AMD. Positions in Snowflake (SNOW) and Novo Nordisk (NVO) were sold-in-full, w/a small reduction in XBI (Biotech). Fund started selling NVO early Q3, sold-in-full by August. Position did good, 8th best performer YTD. Started buying NVO back in Oct '23, in the mid \$90s, kept buying thru December. Started selling ~125, selling most ~135, good for ~+35%. Snowflake not so good, sold-in-full in July, and 3rd worst performer of the year. Snowflake has been in a nasty bear market since February, remains on watch list, but no real interest as of yet. Looking further into Vertiv, fund's 7th largest position, and the fund's best position of the year, within just over 2 months. Fund bought VRT thru early August '24 w/an avg cost ~72. Reduced position slightly in Sept around \$100. VRT is a key player in the AI industry ecosystem, providing digital infrastructure, power, and cooling. Looking for 15% sales growth with '25 EPS growth of 40%+. Would get '25 revenue up to \$9 Billion, and '25 eps up to \$4. 1-2 year target @ \$160, another 60% upside. Can read more about Vertiv here: [Vertiv Investor Relations](#)

Below shows reporting created & analyzed within Data Analytics software, Tableau Software, which has data integration into the fund's internal database/spreadsheets. (*Portfolio Data as of July 2024)

High Level allocation heat map and pie chart:




Below shows the further breakdown of only the fund's equity exposure.




Performance Analysis: Analyzing the breakdown of the Fund's performance, as well as comparisons to other investment vehicles/index, such as the S&P 500, \$BRK-b (Warren Buffett's 'Berkshire Hathaway'), ACWX which tracks Global Markets minus the US (World x-US), and the Russell 2000 small cap index (\$IWM)


FVAM fund, 2nd Quarter 2024




FVAM fund, cumulative return since March




FVAM fund (green) vs SPX (S&P 500, orange), Q2 2024, weekly




FVAM fund (green) vs SPLV (S&P 500 low-volatility, orange), cumulative, Jan '23 thru Q2-2024




FVAM fund (green, left) vs BRK/b (blue, right), Jan '23 thru June '24, Weekly
 (\$BRK-B : Berkshire Hathaway B-shares)




FVAM fund (green, left) vs BRK/b (blue, right), Q2 2024, Weekly




FVAM vs BRK/b and relative return (FVAM vs BRK/b), 1yr
 (excess: positive = outperformance, negative = underperformance)




FVAM vs BRK/b and relative return (FVAM vs BRK/b), Q2 2024
 (excess, positive = outperformance, negative = underperformance)




FVAM (Green) vs IBB (BioTech Index Fund) vs BRK/b (Berkshire Hathaway) vs QQQ (Nasdaq-100), Q2 '24




FVAM (green) vs S&P500 vs BRK/b (Berkshire Hathaway) vs ACWI (World Index) vs IBB (BioTech Index Fund) vs LQD (Bonds) vs EEM (Emerging Markets) vs QQQ (Nasdaq), 2024 thru June.




FVAM vs SPX and relative return (FVAM vs SPX), Q2 - 2024, weekly
 (*excess return shows relative performance)




FVAM vs SPX and relative return (FVAM vs SPX), 2-year




FVAM vs IWM (small caps) vs IBB (biotech) vs SPX (S&P 500) vs ACWI (world index) vs ACWX (world x-US) vs LQD (bonds), Weekly, Q2




FVAM vs S&P 500 (\$SPX) vs Berkshire Hathaway (\$BRK/b) vs \$SPLV (S&P500 Low Volatility etf) vs \$ACWX (World Index x-US etf), Weekly, Q2




FVAM (green) vs EEM (Emerging Markets) , from April '20




FVAM (green) vs LQD (Investment Grade Corporate Bonds), since April '23



S&P 500 (orange) vs ACWX (blue, World Index minus U.S.), Q2 2024, Weekly



FVAM vs ACWI (World Index), with Relative Return (excess return), since YTD '24




FVAM (green) vs ACWX (World Index minus USA, blue) vs S&P 500, 1-year, monthly returns



Reference 1: FVAM Fund Performance Stats (showing view of June 2024, FVAM vs SPX, Statistics)

The data below, displaying just June 2024 in this example, shows performance statistic data maintained daily, showing the FVAM fund vs the S&P 500, even though FVAM is not trying to match or mimic the actual underlying stocks, within the S&P 500, or match the performance of the index. Data shows performance for FVAM, performance for the S&P 500 (\$SPX), as well as relative performance and mathematical statistics (showing risk & volatility). The chart displays daily performance for both FVAM (green) and SPX (blue). Another very important factor for FVAM is to be less volatile than the SPX, which is being analyzed using Statistics, such as Standard Deviation (SDDEV). Excess Return shows relative performance between FVAM and \$SPX (outperformance positive, or underperformance negative). Index C shows plus or minus on a progressive (rolling) basis through the month. The "match (golf)" column also shows that progressive relative performance, but for larger outperformance or underperformance, using a 50bp (+/- 0.5%) differential.

June 2024



*SPX (S&P500 index), BRK/B (Berkshire Hathaway) and any other index/fund/investment vehicles' performance using internal data tracking and data from multiple public internet sources, "non-official" data only.

Heat Map for the Nasdaq-100, showing each stock within that index/sector along with its relative size and weight compared to the overall index (**larger the block size the larger percentage that stock makes up within the index**)
 (*as of early September 2024)



